We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+16.5%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.25B
AUM Growth
+$394M
Cap. Flow
+$407M
Cap. Flow %
18.04%
Top 10 Hldgs %
64.72%
Holding
86
New
21
Increased
10
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
NUVB icon
Nuvation Bio
NUVB
+$148M
2
ANAB icon
AnaptysBio
ANAB
+$99.1M
3
KURA icon
Kura Oncology
KURA
+$60.7M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$39.7M
5
DSGN icon
Design Therapeutics
DSGN
+$38.4M

Top Sells

Rank Stock Value
1
AMTI
Applied Molecular Transport Inc. Common Stock
AMTI
+$44.3M
2
GERN icon
Geron
GERN
+$30.1M
3
VINC
Vincerx Pharma, Inc. Common Stock
VINC
+$10M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$9.77M
5
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$7.51M

Sector Composition

Rank Sector Weight
1 Healthcare 98.25%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
76
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
– –
-46,666
Closed -$4.62M
GOSS icon
77
Gossamer Bio
GOSS
$101M
– –
-294,221
Closed -$2.85M
STRO icon
78
Sutro Biopharma
STRO
$386M
– –
-9,342
Closed -$2.03M
VINC
79
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-24,025
Closed -$10M
CERE
80
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-400,000
Closed -$6.63M
ICPT
81
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
– –
-25,300
Closed -$625K
SURF
82
DELISTED
Surface Oncology, Inc. Common Stock
SURF
– –
-48,558
Closed -$449K
EUCRU
83
DELISTED
Eucrates Biomedical Acquisition Corp. Unit
EUCRU
– –
-200,000
Closed -$2.13M
TMPMU
84
DELISTED
Turmeric Acquisition Corp. Unit
TMPMU
– –
-100,000
Closed -$1.03M
PANA.U
85
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
– –
-390,000
Closed -$4.98M
CMAX
86
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
– –
-16,053
Closed -$7.51M
1 2 3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q1 2021 Portfolio in Review

As of Q1 2021, EcoR1 Capital held 86 positions worth $2.25B, up 21% from $1.86B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

EcoR1 Capital deployed $407M of net new capital in Q1 2021, opening 21 new positions and adding to 10 existing holdings. Its largest new stake was Nuvation Bio: 13,247,017 shares worth $138M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 94% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Applied Molecular Transport Inc. Common Stock, an estimated $44.3M trimmed.

  • EcoR1 Capital's largest Q1 2021 buy was Nuvation Bio: 13,247,017 shares worth $138M.
  • EcoR1 Capital added most to AnaptysBio in Q1 2021, an estimated $99.1M increase.
  • EcoR1 Capital's biggest Q1 2021 reduction was Applied Molecular Transport Inc. Common Stock, cutting an estimated $44.3M.
  • EcoR1 Capital fully exited Geron in Q1 2021, selling an estimated $30.1M.
  • EcoR1 Capital's ten largest holdings make up 65% of its $2.25B portfolio in Q1 2021.
  • EcoR1 Capital opened 21 new positions and closed 15 in Q1 2021.
  • EcoR1 Capital's portfolio value rose 21% quarter-over-quarter to $2.25B.

Based on EcoR1 Capital's 13F filing for Q1 2021, filed 17 May 2021.